Inovio Pharmaceuticals Investors Have Chance to Lead Securities Fraud Class Action Lawsuit

Important Legal Opportunity for Inovio Shareholders

On March 11, 2026, the Law Offices of Howard G. Smith announced a significant legal opportunity for investors who suffered losses in Inovio Pharmaceuticals, Inc. (NASDAQ: INO). This announcement comes as part of a broader securities fraud class action lawsuit that aims to hold the company's leadership accountable for misleading statements and undisclosed operational deficiencies.

Understanding the Allegations

The complaint filed against Inovio claims that from October 10, 2023, to December 26, 2025, the company failed to disclose crucial information to shareholders. Specifically, it is alleged that the defendants did not inform investors about deficiencies in the manufacturing of Inovio's CELLECTRA device. This failure raises doubts regarding Inovio's ability to submit the Biologics License Application (BLA) for the INO-3107 product to the FDA within the anticipated timeline and casts a shadow over the device's overall regulatory and commercial prospects.

The core allegations indicate that:
1. The manufacturing process for the CELLECTRA device was inadequate, undermining the company’s claims of efficiency.
2. Due to these manufacturing issues, Inovio was unlikely to meet the ambitious deadline of submitting the INO-3107 BLA by the latter half of 2024.
3. The company lacked sufficient information to justify claims about the BLA's eligibility for expedited FDA approval.
4. The reputed positive statements from the company regarding its business operations and prospects were misleading, lacking a solid basis in reality.

Call to Action for Affected Investors

Investors who have faced financial losses as a result of these issues are encouraged to contact the Law Offices of Howard G. Smith by April 7, 2026, to potentially take on a lead plaintiff role in the ongoing class-action lawsuit. By participating, investors may assert their rights and seek compensation for the losses incurred.

The firm emphasizes that affected investors do not need to take immediate action other than reaching out for further information. Individuals can choose to retain their own counsel or remain a passive member of the class action. This presents a pivotal moment for those who seek accountability for their losses.

For more details on this legal opportunity or any questions regarding your potential involvement in the lawsuit, please reach out via email at [email protected], or by phone at (215) 638-4847. Additional information can also be found on their official website at www.howardsmithlaw.com.

Conclusion

The allegations against Inovio Pharmaceuticals highlight the importance of transparency and accountability in corporate governance. As shareholders face an uncertain future, those impacted by this alleged securities fraud should consider their legal options to protect their investments. The timeline is crucial, and acting promptly could provide a pathway to recovering losses amidst the unfolding legal situation.